A

Aptorum Group Limited (APM)

NCM – Real vaqt narxi. Valyuta: USD

0.82

+0.01 (1.37%)

Yopilishda: May 12, 2026, 4:00 PM EDT

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Barcha huquqlar himoyalangan.

Foydalanish shartlari

A

Aptorum Group Limited (APM)

NCM – Real vaqt narxi. Valyuta: USD

0.82

+0.01 (1.37%)

Yopilishda: May 12, 2026, 4:00 PM EDT

25.03.2026

Andean Precious Metals Corp. (APM:CA) Q4 2025 Earnings Call Transcript

10.03.2026

Aptorum Group and DiamiR Biosciences Announce Publication of microRNA Glioblastoma Biomarker Study in Diagnostics in Collaboration with the University of Pennsylvania

NEW YORK, NY; NEW HAVEN, CT; and PRINCETON, NJ, March 10, 2026 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, and DiamiR Biosciences Corp. (“DiamiR”), a developer of innovative blood-based diagnostic tests for brain health and other diseases, today announced the publication of a paper by Giliberto, et. al. titled "Development of microRNA-Based Glioblastoma Biomarkers Using Blood Plasma Specimens” in Diagnostics, (https://doi.org/10.3390/diagnostics16050791), a leading peer-reviewed journal focused on clinical diagnostics and biomarker research.

02.02.2026

Aptorum Group Announces a Collaboration Between DiamiR Biosciences and Instant NanoBiosensors (INB) to Validate INB's Automated APOE Testing Platform for Alzheimer's Disease

NEW YORK, NY; NEW HAVEN, CT; PRINCETON, NJ, and TAIPEI, TAIWAN, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, DiamiR Biosciences Corp. (“DiamiR”), a developer of innovative blood-based diagnostic tests for brain health and other diseases, and Instant NanoBiosensors Co., Ltd. (“INB”), a developer of cutting-edge biosensor platforms designed to improve biomedical research and diagnostic processes through simple, reliable, and affordable detection solutions, today announced a collaboration between DiamiR and INB to validate INB's automated APOE testing platform for clinical use in DiamiR's CLIA-certified, CAP-accredited clinical laboratory.

19.11.2025

DiamiR Biosciences and Aptorum Group Announce Two Abstracts Accepted for Presentation at the Clinical Trials on Alzheimer's Disease (CTAD) 2025 Conference

NEW YORK, NY, NEW HAVEN, CT, and PRINCETON, N.J., Nov. 19, 2025 (GLOBE NEWSWIRE) -- DiamiR Biosciences Corp. (“DiamiR”), a developer of innovative blood-based diagnostic tests for brain health and other diseases, and Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, announce two poster presentations at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference, taking place December 1-4, 2025, in San Diego, CA, and online.

12.11.2025

Andean Precious Metals Corp. (APM:CA) Q3 2025 Earnings Call Transcript

Andean Precious Metals Corp. ( APM:CA ) Q3 2025 Earnings Call November 12, 2025 9:00 AM EST Company Participants Amanda Mallough Alberto Morales - Founder, CEO & Executive Chairman Yohann Bouchard - President & Director Juan Sandoval - Chief Financial Officer Dom Kizek Conference Call Participants Omeet Singh - SCP Resource Finance LP, Research Division Allison Carson - Desjardins Securities Inc., Research Division Ben Pirie - Atrium Research Corporation Presentation Operator Hello, and welcome to the Andean Precious Metals Third Quarter Conference Call and Webcast. [Operator Instructions] I would now like to turn the conference over to Amanda Mallough, Director of Investor Relations.

04.08.2025

Aptorum Group Limited Regains Compliance with NASDAQ's Minimum Bid Price Requirement

NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group," “Aptorum” or the "Company"), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, today announced that it received formal written notification from The Nasdaq Stock Market, LLC (“Nasdaq”) confirming that the company has regained compliance with Nasdaq's minimum bid price requirement.

16.07.2025

Aptorum Group Limited and DiamiR Biosciences Enter into Definitive Merger Agreement

NEW YORK, July 16, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group," “Aptorum” or the "Company"), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs in oncology and infectious diseases, and DiamiR Biosciences (“DiamiR”), a developer of proprietary innovative blood-based tests for brain health and other diseases with a CLIA licensed, CAP accredited clinical laboratory in New Haven, CT, today announced that they have entered into a definitive agreement for an all-stock merger transaction, in which DiamiR Biosciences will retain its name and become a wholly-owned subsidiary of Aptorum Group upon consummation of the merger.The combined company expects to remain listed on the Nasdaq Stock Market following the closing of the merger.

Videolar

No Data

There is no data to display

Press-relizlar

10.03.2026

Aptorum Group and DiamiR Biosciences Announce Publication of microRNA Glioblastoma Biomarker Study in Diagnostics in Collaboration with the University of Pennsylvania

NEW YORK, NY; NEW HAVEN, CT; and PRINCETON, NJ, March 10, 2026 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, and DiamiR Biosciences Corp. (“DiamiR”), a developer of innovative blood-based diagnostic tests for brain health and other diseases, today announced the publication of a paper by Giliberto, et. al. titled "Development of microRNA-Based Glioblastoma Biomarkers Using Blood Plasma Specimens” in Diagnostics, (https://doi.org/10.3390/diagnostics16050791), a leading peer-reviewed journal focused on clinical diagnostics and biomarker research.

02.02.2026

Aptorum Group Announces a Collaboration Between DiamiR Biosciences and Instant NanoBiosensors (INB) to Validate INB's Automated APOE Testing Platform for Alzheimer's Disease

NEW YORK, NY; NEW HAVEN, CT; PRINCETON, NJ, and TAIPEI, TAIWAN, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, DiamiR Biosciences Corp. (“DiamiR”), a developer of innovative blood-based diagnostic tests for brain health and other diseases, and Instant NanoBiosensors Co., Ltd. (“INB”), a developer of cutting-edge biosensor platforms designed to improve biomedical research and diagnostic processes through simple, reliable, and affordable detection solutions, today announced a collaboration between DiamiR and INB to validate INB's automated APOE testing platform for clinical use in DiamiR's CLIA-certified, CAP-accredited clinical laboratory.

19.11.2025

DiamiR Biosciences and Aptorum Group Announce Two Abstracts Accepted for Presentation at the Clinical Trials on Alzheimer's Disease (CTAD) 2025 Conference

NEW YORK, NY, NEW HAVEN, CT, and PRINCETON, N.J., Nov. 19, 2025 (GLOBE NEWSWIRE) -- DiamiR Biosciences Corp. (“DiamiR”), a developer of innovative blood-based diagnostic tests for brain health and other diseases, and Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, announce two poster presentations at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference, taking place December 1-4, 2025, in San Diego, CA, and online.

04.08.2025

Aptorum Group Limited Regains Compliance with NASDAQ's Minimum Bid Price Requirement

NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group," “Aptorum” or the "Company"), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, today announced that it received formal written notification from The Nasdaq Stock Market, LLC (“Nasdaq”) confirming that the company has regained compliance with Nasdaq's minimum bid price requirement.

Search stocks

Aptorum Group Limited (APM)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Aptorum Group Limited (APM)

Andean Precious Metals Corp. (APM:CA) Q4 2025 Earnings Call Transcript

Aptorum Group and DiamiR Biosciences Announce Publication of microRNA Glioblastoma Biomarker Study in Diagnostics in Collaboration with the University of Pennsylvania

Aptorum Group Announces a Collaboration Between DiamiR Biosciences and Instant NanoBiosensors (INB) to Validate INB's Automated APOE Testing Platform for Alzheimer's Disease

DiamiR Biosciences and Aptorum Group Announce Two Abstracts Accepted for Presentation at the Clinical Trials on Alzheimer's Disease (CTAD) 2025 Conference

Andean Precious Metals Corp. (APM:CA) Q3 2025 Earnings Call Transcript

Aptorum Group Limited Regains Compliance with NASDAQ's Minimum Bid Price Requirement

Aptorum Group Limited and DiamiR Biosciences Enter into Definitive Merger Agreement

Videolar

No Data

Press-relizlar

Aptorum Group and DiamiR Biosciences Announce Publication of microRNA Glioblastoma Biomarker Study in Diagnostics in Collaboration with the University of Pennsylvania

Aptorum Group Announces a Collaboration Between DiamiR Biosciences and Instant NanoBiosensors (INB) to Validate INB's Automated APOE Testing Platform for Alzheimer's Disease

DiamiR Biosciences and Aptorum Group Announce Two Abstracts Accepted for Presentation at the Clinical Trials on Alzheimer's Disease (CTAD) 2025 Conference

Aptorum Group Limited Regains Compliance with NASDAQ's Minimum Bid Price Requirement